Merck’s ex-official appointed as new R&D head for Johnson & Johnson, Pharma giant opens door for further M&As
Category: #health  By Satarupa De  Date: 2017-06-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Merck’s ex-official appointed as new R&D head for Johnson & Johnson, Pharma giant opens door for further M&As

Johnson & Johnson, Inc., one of the most reputed and popular companies operating in global pharmaceutical market, has appointed a new head - Mathai Mammen, for its research & development wing, as a part of its routine organization restructuring program. Preceding this appointment was former R&D head William Hait’s appointment as global head, J&J external innovation. Through this position, Hait aims to oversee Johnson & Johnson’s partnering portfolio, replete with numerous agreement with reputed companies all over the globe.

As per reports, Hait had already catapulted the pharma giant to a profitable position across the globe, by means of enabling lucrative partnerships and collaborations. This restructuring, say company insiders, will only serve to be highly fruitful to the organization from the business point of view. For one, Hait’s appointment as global head, J&J external innovation has entrusted him with the responsibility of the firm’s JLABS startup incubators, JJDC VC wing, and the innovation centers J&J has set up in MA, London, CA, Boston, Menlo Park, Shanghai, and United Kingdom. Hait’s decade long experience as R&D head is expected to serve him well and do justice to his new posting. The company aims to attract an extensive number of investors and strengthen their global network.

Hait’s arrival at Johnson & Johnson as the head of R&D for the hematology and oncology disciplines 10 years earlier was marred by the company’s efforts to consolidate the teams working across numerous units of aforementioned therapeutic areas. Hait however, oversaw the research with diligence and as reports have it, he successfully established J&J as a force to reckon with, by means of commercializing drugs such as Darzalex, the first monoclonal antibody that was approved by the FDA to be used in the treatment of multiple myeloma.

Mathai Mammen, one of the most prominent ex-executives of Merck, and the co-founder of Theravance Biopharma, the reputed biopharmaceutical company headquartered in San Francisco, has had an impressive record in R&D, possibly owing to which he had been lured away by J&J as the new R&D head. Mammen’s experience as a senior Vice-President in Theravance and as a senior position of R&D in Merck will help catapult Johnson & Johnson to greater heights, given that Hait has already provided Mammen with a pipeline that he reportedly mentioned was one of the most sustainable and robust ones in the industry.

This restructuring is anticipated to bring in renewed growth prospects for J&J. With Hait already having established a pipeline of lucrative mergers, Mammen’s profile has apparently turned more challenging, for which the eminent ex-Merck-executive will have to ante up his performance level and jelp Johnson & Johnson achieve its recently set targets for sales growth and new approvals.



About Author

Satarupa De

Email: [email protected]   

Satarupa De

Satarupa develops content for Market Size Forecasters, Algosonline, and various other portals. An electrical engineer by qualification, she worked for two years in the core domain before switching her professional genre. Following her childhood passion, she opted for ...

Read More

More News By Satarupa De

Merck & WUSTL tie up to study gut bacteria with the help of CRISPR
Merck & WUSTL tie up to study gut bacteria with the help of CRISPR
By Satarupa De

Globally acclaimed genome editing leader, Merck has scarcely announced its strategic collaboration with the Washington University in St. Louis in a quest to optimize nutritional supplements. Apparently, this research c...

Boeing & Airbus push boundaries, enter after-sales service market
Boeing & Airbus push boundaries, enter after-sales service market
By Satarupa De

Riding high on the success of transcontinental airliners, renowned aircraft manufacturers Boeing and Airbus apparently now, are aiming to penetrate after-sales service market. Reportedly, these aircraft giants are set ...

Fox acquires seven of Sinclair’s broadcasting stations for $1.5bn
Fox acquires seven of Sinclair’s broadcasting stations for $1.5bn
By Satarupa De

Fox Broadcasting Co. has apparently signed an agreement with Sinclair Broadcast Group to purchase some of its television stations for a valuation of USD 1.5 billion. Allegedly, in a bid to win the Federal approval for ...